Green Cross Concludes Takeover Deal Of Innocell; Looks To Overseas Markets For Growth
This article was originally published in PharmAsia News
Korea’s Green Cross to continue development of Innocell’s Immuncell-LC cancer cell therapy after becoming the major shareholder of the troubled company.
You may also be interested in...
SEOUL - Korea vaccine leader Green Cross Corp. and LG Life Sciences Ltd. have teamed up to co-promote Shinbaro, a first-line osteoarthritis treatment developed by Green Cross that could compete against Pfizer Inc.'s Celebrex
Multiple IPF drugs are being rushed into Phase III based on early-stage signals of efficacy and safety presented at the ATS meeting. Scrip spoke with the University of Pittsburgh's Kevin Gibson about the candidates, trial design, combination therapy and limitations of current therapy.
Phase III studies testing Dupixent in moderate-to-severe asthma were largely positive, but subgroup details raise questions about how it will compete against biologics targeting the IL-5 pathway. Some experts urge comparison trials to inform physicians' decisions about long-term use.